Ceftin

(cefuroxime axetil)

ApprovedSmall molecule

GGlaxo Dba Glaxosmithkline

Ceftin is one of 51 small molecule programs targeting Urinary Tract Infection. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Urinary Tract InfectionActive, not recruiting

ErythemaActive, not recruiting

PyelonephritisRecruiting

Urinary Tract InfectionPreclinical

Active, not recruiting

ErythemaApproved

Active, not recruiting

PyelonephritisApproved

Recruiting

Competition

Competitive Landscape

39 competitors in Urinary Tract Infection

#DrugCompanyPhaseTrials

Doribax

Shionogi

Approved

6 2

Cipro

Bayer

Approved

6 3

Levaquin

WWim Janssens

Approved

14 4

Ivadantin

PProcter and Gamble

Approved

12 5

Estrace

Novo Nordisk

Approved

2 6

Voltaren

Novartis

Approved

1 7

Acanya

Pfizer

Approved

1 8

Vesicare

Astellas

Approved

1 9

Invanz

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

6 10

Monurol

MMeitheal

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Post-ApprovalRecruiting

Pyelonephritis

NCT06527560

Clinical

Trials by Indication[1]

Erythema2 trials

Comparison of Doxycycline and Cefuroxime Axetil in Erythema Migrans

Completed·UUniversity Medical Centre Ljubljana·N/A·NCT03584919·509 enrolled

Comparison of Doxycycline and Cefuroxime Axetil for Treatment of Erythema Migrans: Clinical and Microbiological Outcome

Completed·UUniversity Medical Centre Ljubljana·Phase 4·NCT01518192·544 enrolled

Urinary Tract Infection1 trial

Does Antibiotic Prophylaxis at Urinary Catheter Removal Prevent Urinary Tract Infections

Unknown status·OOmri Schwarztuch Gildor·N/A·NCT05577273·1,000 enrolled

Clinical Trial1 trial

The Clinical Trial of Cefuroxime Axetil Dispersible Tablets

Unknown status·JJiangsu Famous Medical Technology Co., Ltd.··NCT03020940·100,000 enrolled

Infections1 trial

Preventing Frequent Sinus Infections in HIV-Infected Patients

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000752

Pyelonephritis1 trial

Clinical Trial Comparing Oral Versus Intravenous Cefuroxime in Pregnant Women with Pyelonephritis

Recruiting·HHospital de Clinicas de Porto Alegre·Phase 4·NCT06527560·100 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 28, 1987

CEFTIN

NDA NDA050605

Jun 30, 1994

CEFTIN

NDA NDA050672

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for cefuroxime axetil. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — cefuroxime axetil compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for cefuroxime axetil. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA050672). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Glaxo Dba Glaxosmithkline company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: GGlaxo Dba Glaxosmithkline

Ceftin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Erythema2 trials

Urinary Tract Infection1 trial

Clinical Trial1 trial

Infections1 trial

Pyelonephritis1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News